Last Updated on September 24, 2021 by The Health Master
All Indian children aged 12 or older will become eligible for C-19 vaccinations from next month, when drug maker Cadila Healthcare launches its ZyCoV-D product, two sources with direct knowledge of the matter told Reuters.
The world’s first DNA-based C-19 vaccine, ZyCoV-D won emergency authorisation from Indian regulators last month. From October, the company, better known as Zydus Cadila, will produce 10 million doses a month.
The vaccine is the only one approved for children in India, which has given a total of 825.9 million doses to adults among its population of nearly 1.4 billion.
ZyCoV-D is a three-dose vaccine which will be administered first on day zero, day 28th and then on the 56th day.
It is a needle-free vaccine administered using The Pharma Jet, a needle free applicator – ‘Tropis’, which ensures painless intradermal vaccine delivery.
Last month, the government’s Department of Biotechnology (DBT) said that the “plug-and-play” technology on which the plasmid DNA platform is based can be easily adapted to deal with mutations in the virus, such as those already occurring.